Independent Financial Information Made Easy
The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.
MaxCyte shares fall as revenue plummets in first half, loss widens. CEO Douglas Doerfler said: We will continue to make the necessary investments into key aspects of our technology and support offering, including our applications lab, and process development capabilities, which we believe enable us to provide invaluable support to our partners. MaxCyte is a cellular engineering firm whose proprietary platform allows clients to modify cells. Gilead expands CAR-T deal with Maxcyte, Precision files for $100m IPO. Lyell expands our exposure to solid tumor indications which opens up a significant commercial revenue opportunity for MaxCyte. CEO Douglas Doerfler sold 14,968 shares of Maxcyte stock in a transaction dated Tuesday, June 27th.
Open: 5.14 Close: 5.03 Change: -0.11
Read more →Open: 3.91 Close: 3.84 Change: -0.07
Read more →Open: 4.73 Close: 4.98 Change: 0.25
Read more →